Adults With Upper Limb Spasticity

Overview Efficacy Safety Dosing

Significant Improvement Shown in Studies of Adults with Upper Limb Spasticity (ULS)

XEOMIN® is a prescription medicine that is injected into muscles and used to treat adults with upper limb spasticity.1

Pivotal Trial Design

Significant difference was seen in the mean change on the Ashworth Scale between XEOMIN and placebo (P<0.001)1

Demonstrated Improvements in Muscle Tone as Measured by the Ashworth Scale

Ashworth Scale is a clinical measure of resistance to passive movement1

Improvement in Overall Spasticity as Measured by Global Impression of Change Scale (GICS)

GICS is a global measure of a patient’s functional improvement
The investigators’ GICS scores at week 4 demonstrated that XEOMIN was superior to placebo1
Adverse Reactions

The most commonly observed adverse reactions (incidence ≥2% of patients and greater than placebo) for XEOMIN were seizure (3%), nasopharyngitis (2%), dry mouth (2%), and upper respiratory tract infection (2%).1

References

  1. XEOMIN® [package insert]. Raleigh, NC: Merz North America, Inc; 2018.
  2. Data on file. Raleigh, NC: Merz North America, Inc.
  3. Elovic EP, Munin MC, Kanovsky P, Hanschmann A, Hiersemenzel R, Marciniak C. Randomized, placebo-controlled trial of incobotulinumtoxinA for upper-limb post-stroke spasticity [published online ahead of print]. Muscle Nerve. doi: 10.1002/mus.24776.